Research Paper

Self-generating oxygen enhanced mitochondrion-targeted photodynamic therapy for tumor treatment with hypoxia scavenging

Zhengyang Yang1*, Jiafeng Wang1*, Shichao Ai1*, Jianfei Sun2*, Xiaoli Mai3*, and Wenxian Guan1*

1. Department of General Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, No. 321 Zhongshan Road, Nanjing, 210008, China.
2. School of Biological Science and Medical Engineering, Southeast University, No. 87 Dingjiaqiao, Nanjing, 210009, China
3. Department of Radiology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, No. 321 Zhongshan Road, Nanjing, 210008, China.

*These authors contributed equally to this work.

© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.

Received: 2019.05.25; Accepted: 2019.07.10; Published: 2019.09.20

Abstract

Tumor hypoxia is an important reason for the limited therapeutic efficacy of photodynamic therapy (PDT) because of the oxygen requirement of the therapeutic process. PDT consumes tissue oxygen and destroys tumor vasculature, further hampering its own efficacy in promoting tumor deterioration. Therefore, overcoming the photodynamic exacerbation of tumor hypoxia is urgent.

Methods: Herein, we report a photodynamic nanoparticle with sustainable hypoxia remission skills by both intratumoral H2O2 catalysis and targeted mitochondrial destruction. The Mn3O4@MSNs@IR780 nanoparticles are formed by absorbing a photosensitizer (IR780) into 90 nm mesoporous silica nanoparticles (MSNs) and capping the surface pores with 5 nm Mn3O4 nanoparticles.

Results: These Mn3O4 nanoparticles can accumulate in tumors and respond to the H2O2-enriched tumor microenvironment by decomposing and catalyzing H2O2 into O2. Afterwards, IR780 is released and activated, spontaneously targeting the mitochondria due to its natural mitochondrial affinity. Under laser irradiation, this self-generated oxygen-enhanced PDT can destroy mitochondria and inhibit cell respiration, resulting in sustainable hypoxia remission in tumor tissues and consequently enhancing the therapeutic outcome. In vitro experiments suggest that Mn3O4@MSNs@IR780 exhibited highly mitochondrion-targeted properties and could sustainably inhibit tumor hypoxia. Additionally, the highest photoacoustic signal of HbO2 with the lowest Hb was observed in tumors from mice after PDT, indicating that these nanoparticles can also prevent tumor hypoxia in vivo.

Conclusion: Taken together, our study indicated a new approach for overcoming the sustainable hypoxia limitation in traditional PDT by targeted oxygen supplementation and mitochondria destruction.

Key words: mitochondrion targeting, endogenous oxygen generation, photodynamic therapy, tumor hypoxia, NIR fluorescence imaging.

Introduction

Hypoxia has been recognized as one of the hostile hallmarks of most solid tumors due to the increasing metabolic processes of the destructively proliferating carcinoma cells, which eventually leads to a scant oxygen supply in the tumor microenvironment [1, 2]. Hypoxia is also recognized as a dangerous factor that can cause tumor metastasis and angiogenesis [3, 4]. The insufficient oxygen in tumor tissues is one of the major obstacles in successful photodynamic therapy (PDT) [5-7]. As
photochemical reactions require oxygen, PDT efficacy decreases exponentially with the consumption of oxygen during therapy, thus requiring a constant supply of oxygen [8-13]. Additionally, the tumor hypoxic microenvironment may be exacerbated by the sustained consumption of oxygen in PDT [14].

Thus far, there have been different strategies to overcome the limitation of hypoxia limitation and consequently to improve PDT efficacy, such as transporting additional oxygen by perfluorocarbon, providing hyperbaric oxygen by inhalation and catalyzing endogenous H_2O_2 to O_2 [15-17]. Among these methods, the in situ production of oxygen via the employment of nanomaterials as a catalyst is the most effective. For instance, MnO_2 and its various nanocomposites have recently attracted much attention as bioactive materials that can regulate oxygen in tumor hypoxia by the decomposition of endogenic H_2O_2 [18-20]. However, these approaches face the severe problem that tumor hypoxia cannot be inhibited sustainably because the uninterrupted and heightened respiration in tumors consumes oxygen through the mitochondria. Mitochondria, as indispensable organelles responsible for cell respiration, have recently been indicated to play key roles in various human diseases, particularly malignancies [21, 22]. Sustained respiration through the mitochondria may worsen tumor hypoxia, and mitochondria are always considered target organelles when designing targeted cancer therapy [23, 24]. Therefore, the design of nanocomposites that can selectively destroy mitochondria and sustainably produce O_2 in hypoxic tumors is of paramount importance.

As a lipophilic cation, the near-infrared photosensitizer IR780 was found to accumulate predominantly in the mitochondria of tumor cells because of the higher mitochondrial membrane potential in tumor cells [25] (Figure S1). Mitochondrion-targeting PDT agents can rapidly damage the biological functions of the organelles under normal oxygen conditions, leading to the cell death of tumor cells. Moreover, the destruction of mitochondrial biological functions can inhibit cellular respiration within cancer cells, thus reducing oxygen consumption [26, 27]. The vulnerability of mitochondria to reactive oxygen species (ROS) is a critical factor in designing a PDT system [28, 29]. Based on these therapeutic approaches, in this work, a versatile nanocomposite (Mn_3O_4@MSNs@IR780) has been designed to concurrently achieve mitochondrial-targeted drug delivery, oxygen release, enhanced photodynamic therapy and sustained inhibition of hypoxia. Manganese oxide nanocrystals (Mn_3O_4 nanoparticles), which serve as gatekeepers, block the hydrophobic photosensitizer IR780-loaded channels of MSNs. H_2O_2 is one of the tumor metabolites (present at high amounts, up to 1 mM), and Mn_3O_4 nanoparticles in this study act as an efficient catalyst to continually break down H_2O_2 to oxygen without external activation [30-32]. Moreover, the H_2O_2-responsive disintegration of Mn_3O_4 nanoparticles leads to oxygen generation and switch opening. Afterwards, IR780 dissociated and released in tumor tissues further specifically targets mitochondria because of its unique properties. Under the synergistic effect of oxygen and 808 nm laser irradiation, ROS are generated near mitochondria and damage them, further inhibiting cell respiration and leading to apoptosis of tumor cells (Scheme 1). The combined application of mitochondrial respiratory depression and self-generated oxygen may open a new path toward enlarging PDT curative effects.

Scheme 1 Schematic diagram of the synthetic processes of Mn_3O_4@MSNs@IR780, the H_2O_2 triggered release of IR780 and O_2, and the mitochondria targeted PDT.
Experimental section

Materials and instrumentation

Manganese acetate, N,N-dimethylformamide (DMF), 3-aminopropyltriethoxysilane (APTES), cetyltrimethylammonium bromide (CTAB), tetraethyl orthosilicate (TEOS, 99.98%), absolute ethanol, succinic anhydride, triethylamine, dimethyl sulfoxide (DMSO), 1-(3-(dimethylamino)propyl)-3-ethylcarbodiimide hydrochloride (EDC·HCl) and IR780 were purchased from Sigma-Aldrich. The Hydrogen Peroxide (H2O2) Colorimetric Assay Kit, Singlet Oxygen Sensor Green (SOSG), MitoTracker® Green FM, LysoTracker Green DND-26, the Reactive Oxygen Species Assay Kit, the ROS-ID™ Hypoxia/Oxidative Stress Detection Kit, the Membrane and Cytosol Protein Extraction Kit, PVDF membrane, Cell Counting Kit-8 and the Calcein-AM/PI Kit were purchased from Keygen Biotechnology.

The morphology of the nanocomposite was studied by transmission electron microscopy (TEM, FEI F20), high resolution TEM (JEOL, TEM-2100), field-emission scanning electron microscopy (SEM, JEOL) and dynamic light scattering (DLS, Nano-ZS90, Malvern, UK). The zeta potential of these nanoparticles was monitored by Zetaplus (Brookhaven Instruments Corporation). The fluorescence of IR780 and Mn3O4@MSNs@IR780 nanoparticles were detected using Fluoromax-4 spectrofluorometer (HoribaScientific, Edison, Nanjing). The stability of Mn3O4@MSNs@IR780 nanoparticles were monitored through their DLS and Zeta potential results every 12 h in PBS and serum. Structure characterization was performed via wide/small-angle X-ray diffraction (XRD) (Rigaku D/Ma 2550). Nitrogen adsorption–desorption isotherms were collected by an Autosorb iQ2 adsorbptometer at 77 K. Fourier transform infrared (FTIR) spectroscopy (Nicolet Impact 410) and UV-vis-NIR spectroscopy (Shimadzu UV-3600) were used to determine the loading and release of IR780 or H2O2. The X-ray photoelectron spectroscopy (XPS) results were detected using an ESCALAB 250 spectrometer. A portable dissolved oxygen meter (YSI, 550A, Japan) was used to measure the production of oxygen.

Synthesis of amine-functionalized Mn3O4

Mn3O4 nanoparticles were synthesized by the thermal decomposition of manganese acetate. Ten milliliters of manganese acetate was dissolved in 50 mL of DMF and loaded into a flask. Then, the temperature was raised to 130 °C. After stabilization of the temperature, 500 µL of APTES was injected into the above solution, and a brown precipitate of amine-functionalized Mn3O4 nanoparticles was produced. The product was then centrifuged and washed three times with absolute ethanol.

Synthesis of carboxyl-functionalized MSNs

Amine-functionalized MSNs of MCM-41 types (100 nm) were synthesized according to the following methods. First, 0.5 g CTAB (1.35 mmol) was dissolved in 240 mL of water. Then, 1.7 mL sodium hydroxide aqueous solution (2.00 M) was added to the CTAB solution, and the temperature of the mixture was raised to 80 °C. After achieving the desired temperature, 2.5 mL TEOS (11.2 mmol) and 250 µL APTES were successively added dropwise to the above alkaline surfactant solution under vigorous stirring. The mixture was stirred for 2 h to obtain a white precipitate. The resulting solid product was filtered, washed with water and ethanol, and dried at 60 °C. Next, 50 mg of MSNs-NH2 was further functionalized with carboxyl moieties using 5 mg of succinic anhydride and 5 µL of triethylamine in 10 mL of DMSO at 50 °C for 24 h.

Preparation of MSNs@IR780

The photosensitizer IR780 (ethanolic solution 5 mg/mL) was loaded into carboxyl-functionalized MSNs (50 mg) by sonication, followed by stirring for 10 h at room temperature. The green MSNs@IR780 powder was centrifuged and washed three times with ethanol and water. The loading amount of IR780 was determined by collection of the unloaded remaining solution and washings of IR780.

Preparation of Mn3O4@MSNs@IR780

EDC chemistry was used to anchor Mn3O4 nanoparticles onto the surface of MSNs@IR780. Typically, 5 mg of EDC·HCl, 20 mg of MSNs@IR780, and 100 mg of Mn3O4 nanoparticles were dispersed into 5 mL of water, and the solution was stirred for 30 min. The Mn3O4@MSNs@IR780 nanocomposite was collected by centrifugation afterwards.

Responsive IR780 release, oxygen production and PDT characterization

To analyze the catalytic ability of Mn3O4@MSNs@IR780 to generate oxygen from H2O2, a Hydrogen Peroxide (H2O2) Colorimetric Assay Kit (Elabscience Biotechnology, Wuhan, China) was used to determine the concentration of H2O2 over the course of investigation at 405 nm absorbance. The disintegration of Mn3O4 incubated in 1 mM H2O2 after 24 h was revealed through the appearance of the Mn2p peak in the XPS spectrum. A portable dissolved oxygen meter was used to measure the real-time oxygen concentration with the oxygen electrode
probe immersed in the solution after adding Mn₃O₄@MSNs@IR780 into 1 mM H₂O₂. The control release performance of IR780 was determined by measuring the absorbance of IR780 at 780 nm using UV-vis-NIR. The relevant pH-dependent and glutathione (GSH)-dependent decomposed behavior of Mn₃O₄@MSNs@IR780 were measured through the manganese (Mn²⁺) percentage concentration determined by ICP analysis.

The PDT characterization of Mn₃O₄@MSNs@IR780 was monitored using a 1O₂-sensitive SOSG probe (Thermo Fisher Scientific, MA, USA). Briefly, 0.1 mL samples and 0.02 mL SOSG (50 μM) were added to 96-well plates without lighting. A multifunctional plate reader (Tecan Safire, Switzerland) was then used to measure the absorbance and fluorescence (λ_{ex} / λ_{em} = 488 nm / 520 nm) after 808 nm laser irradiation (1 W cm⁻², 5 min) under hermetically sealed conditions. The final IR780 concentration is 5 µg mL⁻¹.

**Cells and cell culture**

The human gastric cancer cell line MKN-45P was obtained from the Shanghai Institute of Cell Biology, Chinese Academy of Sciences (Shanghai, China) and cultured in RPMI-1640 medium supplemented with 10% heat-inactivated FBS, 1% penicillin and 100 g mL⁻¹ streptomycin at 37 °C with 5% CO₂.

**Subcellular localization of Mn₃O₄@MSNs@IR780**

The subcellular localization of Mn₃O₄@MSNs@IR780 was detected by confocal laser scanning microscope (Leica, Wetzlar, Germany). To demonstrate the mitochondrion targeting of IR780, mitochondrion- and lysosome-selective fluorescence probes were used as subcellular location marker. After 4 h of co-culture of MKN-45P cells with Mn₃O₄@MSNs@IR780 and Mn₃O₄@MSNs, MitoTracker® Green FM (λ_{ex} / λ_{em} = 490 nm / 516 nm) and LysoTracker Green DND-26 (λ_{ex} / λ_{em} = 504 nm / 511 nm) were added to label the mitochondria and lysosomes, respectively, for 45 min. After washing three times with PBS, the subcellular localization of Mn₃O₄@MSNs@IR780 and Mn₃O₄@MSNs was observed using confocal laser scanning microscopy (CLSM).

**ROS generation in cancer cells**

ROS generation in cancer cells was detected using a Reactive Oxygen Species Assay Kit (λ_{ex} / λ_{em} = 488 nm / 525 nm). Six groups were established (control, laser, IR780, IR780 + laser, Mn₃O₄@MSNs@IR780 and Mn₃O₄@MSNs@IR780 + laser). All analyses were performed three times. MKN-45P cells were seeded and incubated on a 6-well plate (or in six confocal cell culture dishes) for 12 h. Then, 1 mL of RPMI-1640, 5 µg of IR780 dispersed in 1 mL of RPMI-1640, and Mn₃O₄@MSNs@IR780 dispersed in 1 mL of RPMI-1640 (5 µg IR780) were added to the corresponding wells (or dishes). Cells were incubated for another 4 h at 37 °C and then washed with PBS three times. Subsequently, 1 mL ofDCFH-DA was added to each well (500 µL to each dish) and incubated for another 15 min. Next, the cells were washed three times and irradiated with an 808 nm laser (1 W cm⁻², 5 min). The generation of ROS was then quantitatively measured using flow cytometry (Becton Dickinson Bioscience, San Jose, CA, USA). Meanwhile, the generation of ROS in MKN-45P cells was also observed using CLSM.

**Hypoxia detection in cancer cells**

The ROS-ID™ Hypoxia/Oxidative Stress Detection Kit (Enzo Life Sciences) was used to evaluate the hypoxia conditions in cancer cells. Four groups were established (control, IR780 + laser, Mn₃O₄@MSNs@IR780 and Mn₃O₄@MSNs@IR780 + laser). In addition, we repeated the experiments 6 h after treatment to estimate the ability to sustain the prevention of hypoxia. The experimental methods were identical to those used for ROS detection experiments. Subsequently, the hypoxia/oxidative stress detection mixture was added to confocal cell culture dishes following the manufacturer’s instructions. After incubation for 30 min, the MKN-45P cells were washed with PBS three times and irradiated with an 808 nm laser (1 W cm⁻², 5 min). Next, the ROS signal (λ_{ex} / λ_{em} = 488 nm / 520 nm) and the hypoxia signal (λ_{ex} / λ_{em} = 488 nm / 590 nm) were monitored using CLSM.

Western blot analysis was further conducted to detect the expression of hypoxia inducible factor-1α (HIF-1α) in gastric cancer cells. Total protein in MKN-45P cells was extracted using the Membrane and Cytosol Protein Extraction Kit (Beyotime Biotechnology). Samples were then transferred onto a PVDF membrane (Millipore, MA, USA). The membranes were then blocked with 5% skimmed milk and incubated with the primary antibody, anti-GAPDH and anti-HIF-1α, (Cell Signaling Technology) overnight at 8 °C. Anti-rabbit secondary antibodies were used, and bands were visualized by Pierce chemiluminescent substrate (Thermo Fisher). Photographs were acquired using FLI Capture (Tanon, Shanghai, China) and analyzed using ImageJ software.

**In vitro therapy against cancer cells**

To assess the therapeutic effects of different treatments, MKN-45P cells were seeded in 96-well
plates for 12 h. The groups and experimental approaches were similar to those used for ROS generation detection. The final IR780 concentration was 5 µg mL⁻¹. After 4 h incubation with each sample, MKN-45P cells were washed three times with PBS and then exposed to a 808 nm laser (1 W cm⁻², 5 min per well). Next, 10 µL of Cell Counting Kit-8 (CCK-8) was added to the wells for a further 4 h incubation, and an ELISA microplate reader was used to measure the absorbance values in each well at 450 nm. Each group was examined six times.

Additionally, the Calcein-AM/PI Kit was used to identify living and dead MKN-45P cells. After the 808 nm laser (1 W cm⁻², 5 min) treatment, 200 µL of cancer cell suspension (10⁶ cells) was incubated with 100 µL of CAM/PI Double Stain working solution following the manufacturer’s instructions. Subsequently, the cells were washed three times with PBS. Living cells (λ_ex / λ_em = 490 nm / 515 nm) and dead cells (λ_ex / λ_em = 535 nm / 617 nm) were monitored using CLSM. The counts of green/red cells were analyzed using ImageJ software.

**MKN-45P tumor xenograft model**

Five-week-old male BALB/c nude mice with severe combined immunodeficiency (SCID) were obtained from the Model Animal Research Center of Nanjing University (Nanjing, China). All animal experiments were approved by the Institutional Animal Care and Use Committee (IACUC) of Nanjing University. When the MKN-45P cells reached 90% confluence, they were subcultured at a ratio of 1:3. To establish the MKN-45P tumor xenograft models, a total of 1 × 10⁶ MKN-45P cells were suspended in 100 µL of PBS, then injected subcutaneously into the left flank area of nude mice. The tumor volume was calculated as [π / 6 × length × (width)²].

**In vivo NIR fluorescence imaging and biodistribution**

For *in vivo* NIR fluorescence imaging and biodistribution assessment, a Mn₃O₄@MSNs@IR780 PBS suspension was injected through the tail veins. The final IR780 concentration was 25 µg kg⁻¹ per mouse. These mice were then imaged by the Maestro *in vivo* fluorescence imaging system (Cri Inc., Woburn, MA) before and 0.5, 1, 2, 4, 6, 8, 12, 24, 48 h post injection. Subsequently, the mice were sacrificed, and the main organs and tumor tissues were imaged to detect the biodistribution of Mn₃O₄@MSNs@IR780 at 24 h. Meanwhile, MKN-45P tumor xenograft mice were sacrificed 4, 12, 24, and 48 h after intravenous injection into the tail vein. Tumor tissues and major organs (heart, liver, spleen, lung and kidney) were collected, weighed, and lysed in aqua regia. The content of manganese was measured using a NexION 300D ICP-MS.

**Monitoring tumor hypoxia conditions**

To monitor the tumor hypoxia conditions, the xenograft mice were divided into six groups (control, laser, IR780, IR780 + laser, Mn₃O₄@MSNs@IR780 and Mn₃O₄@MSNs@IR780 + laser). The mice were injected through the tail veins with different agents (PBS, IR780 and Mn₃O₄@MSNs@IR780) and then split into laser and no laser subgroups. The final IR780 concentration was 25 µg kg⁻¹ per mouse. Then, photoacoustic imaging (PA) was performed to monitor the vascular saturated oxygen in tumor tissues 24 h after injection. Oxygenated hemoglobin (HbO₂) was detected at an excitation wavelength of 850 nm and deoxygenated hemoglobin (Hb) at 700 nm using a preclinical photoacoustic computerized tomography scanner (Endra Nexus 128, USA) 24 h after injection. Subsequently, the mice were sacrificed, and tumor tissues were harvested for HIF-1α immunohistochemical analysis. The PA intensity and counts of blue/brown cells were analyzed using ImageJ software.

**In vivo antitumor therapy**

The tumor-bearing MKN-45P xenograft mice were randomly divided into six groups (control, laser, IR780, IR780 + laser, Mn₃O₄@MSNs@IR780 and Mn₃O₄@MSNs@IR780 + laser) when the tumor volume reached approximately 50 mm. The control group was injected with 100 µL of PBS per mouse, while the laser group was injected with 100 µL PBS and then irradiated with an 808 nm laser (1 W cm⁻², 5 min per mouse). The IR780 group was injected with 100 µL IR780 PBS suspension per mouse. The IR780 + laser group was injected with IR780 PBS suspension followed by 808 nm laser (1 W cm⁻², 5 min per mouse). The Mn₃O₄@MSNs@IR780 group was injected with Mn₃O₄@MSNs@IR780 PBS suspension per mouse. The Mn₃O₄@MSNs@IR780 + laser group was intravenously injected with the Mn₃O₄@MSNs@IR780 PBS suspension followed by an 808 nm laser (1 W cm⁻², 5 min per mouse). The final IR780 concentration was 25 µg kg⁻¹ per mouse. The body weight and tumor volume of each mouse were observed and recorded every two days after laser irradiation. After 16 days, the mice were sacrificed, and tumor tissues were collected, washed three times with PBS and weighed. Then, the tumor issues and major organs, including the heart, liver, spleen, lung and kidney, were harvested and fixed in a 4% paraformaldehyde solution. Finally, tumor tissues were stained with hematoxylin and eosin (H & E) and TUNEL for histopathology analysis.
Biosafety analysis of Mn3O4@MSNs@IR780

To observe the pathology changes, major organs (heart, liver, spleen, lung, and kidney) collected from the mice after therapy were fixed in a 4% paraformaldehyde solution at 4 °C for 4 h and then embedded in paraffin. Then, these tissues were stained with H & E, and the histopathologic changes were detected by an optical microscope (Olympus, Japan).

Hematological and biochemical assays were also used to evaluate the in vivo toxicity and biocompatibility of Mn3O4@MSNs@IR780. The mice were anesthetized, and blood was collected from the naked eye for hematological and biochemical assays, including white blood cell (WBC), neutrophil (NEU), lymphocyte (LYM), red blood cell (RBC), hemoglobin (HGB), platelet (PLT), alanine aminotransferase (ALT), aspartate aminotransferase (AST), blood urea nitrogen (BUN) and serum creatinine (Scr) assays.

Statistical analysis

All data were analyzed using GraphPad Prism (version 5.01) software at a significance level of *p < 0.05; **p < 0.01 and ***p < 0.001. All data are presented as the mean ± standard deviation (SD).

Results and Discussion

Synthesis and characterizations of Mn3O4@MSNs@IR780

MSN-based drug nanocarriers were first synthesized and then functionalized with amine moieties, thus improving their water stability and providing anchoring sites for gatekeepers. After IR780 was loaded into functionalized MSNs by sonication, Mn3O4 nanoparticles (5 nm) were anchored as gatekeepers on the IR780-loaded MSNs (MSNs@IR780) using EDC chemistry. Scanning electron microscopy (SEM) and transmission electron microscopy (TEM) images of Mn3O4@MSNs@IR780 showed the uniform distribution and considerable blockade of IR780 molecules by Mn3O4 nanoparticles to prevent IR780 leakage from the MSN nanochannels before reaching the targeted region (Figure 1A-B). TEM images of the Mn3O4 nanoparticles with an average particle diameter of 5 nm are provided in Figure S2.

The size of MSNs was approximately 88 nm, while the size of Mn3O4@MSNs@IR780 was approximately 94 nm (Figure 1C). Additionally, the polymer dispersity index (PDI) value of MSNs and Mn3O4@MSNs@IR780 was about 0.39 and 0.47, indicating that such nanoparticles exhibited well stability and dispersity. The zeta potential of Mn3O4, MSNs, MSNs@IR780 and Mn3O4@MSNs@IR780 was approximately 35 mV, -31 mV, -27 mV and 3 mV, which revealed the successful surface conjugation of Mn3O4 with MSNs@IR780 (Figure 1D). After drug loading and Mn3O4 conjugation, the typical MSN peaks (red arrow) decreased markedly in low-angle X-ray diffraction (XRD) results, demonstrating that holes on their surface might have already been covered by IR780 and Mn3O4 (Figure 1E). During drug loading and surface capping, the BET surface areas of MSNs, MSNs@IR780, and Mn3O4@MSNs@IR780 gradually decreased, as shown in the nitrogen adsorption analysis (Figure 1F). Well-ordered MSN nanopores can be seen in the...
According to the desorption isotherms, the corresponding pore size distributions were calculated for all three samples. As shown in Figure S3B, the pore size of MSNs possesses a narrow distribution at approximately 2.45 nm, while a wide distribution from 1.4 to 2.7 nm was found in the drug-loaded sample. Pore size distribution data of Mn3O4@MSNs@IR780 revealed blockage of the drug-loaded nanopores of MSNs. Meanwhile, both the UV-vis-NIR and Fourier transform infrared (FTIR) spectra of Mn3O4@MSNs@IR780 featured specific absorption peaks of IR780 and Mn3O4, thus implying the successful loading of the hydrophobic photosensitizer and the H2O2 response switch (Figure 1G-H).

The loading amount of IR780 in the MSNs was determined by UV-vis-NIR and found to be as high as 12 mg per 1 g of MSNs. As shown in Figure S4, we could observe the fluorescence of IR780 and Mn3O4@MSNs@IR780 nanoparticles was similar, indicating that fluorescence would not be quenched after loading to MSNs. DLS and Zeta potential of Mn3O4@MSNs@IR780 could maintain stable for 50 h in PBS and serum, demonstrating that these nanoparticles had a superior stability (Figure S5).

**In vitro H2O2 responsive drug release and catalytic/photodynamic effect**

Exposure to a specific high H2O2 concentration in the tumor microenvironment resulted in the steady-state dissolution of these Mn3O4 nanoparticles and the subsequent generation of oxygen [33,34]. To verify the Mn3O4 response to H2O2, wide-angle powder XRD patterns were tested. The characteristic peaks of Mn3O4 decreased markedly in H2O2 solution, indicating the decomposition and abscission of Mn3O4 from the MSNs (Figure 2A). The nitrogen adsorption analysis pointed out the decomposition and abscission of Mn3O4 from Mn3O4@MSNs@IR780 after incubated in H2O2 for 24 h (Figure S6). As shown in Figure S7A, the characteristic peak of Mn3O4 at the wavenumber of about 2500 cm⁻¹ disappeared after incubated in H2O2. The characteristic peak of IR780 also disappeared in Figure S7B, demonstrating that the opening of MSNs channels and further release of drugs. As for the XPS spectrum results, the counts of Mn 2p3/2 and 2p1/2 at BE values of 641.7 eV and 653.7 eV decreased obviously while incubated in H2O2 for 24 h, also indicating the successfully decomposing of Mn3O4 after H2O2 treatment (Figure S7C-F).

Such results above demonstrated that the Mn3O4 nanoparticles were disintegrated and further opened the channels of MSNs. Before H2O2 treatment, the wide-angle XRD pattern of Mn3O4@MSNs@IR780 nanoparticles was well indexed to the tetragonal hausmannite structure (JCPDS 24-07340), while the XPS data showed that the BE values of Mn 2p3/2 and 2p1/2 were 641.7 eV and 653.7 eV, respectively. These results...
indicated the presence of dual oxidation states, Mn$^{2+}$ and Mn$^{3+}$, in the Mn$_3$O$_4$@MSNs@IR780 nanoparticles before reaction with H$_2$O$_2$. According to previous studies [35,36], Mn$_3$O$_4$ nanoparticles possess the catalase-mimicking ability to catalyze endogenous tumor H$_2$O$_2$ into O$_2$, wherein H$_2$O$_2$ acted as the reducing agent and could reduce the trivalent Mn to divalent Mn and break itself down into H$_2$O and O$_2$. In our study, as expected, a transparent solution was observed after Mn$_3$O$_4$@MSNs@IR780 reacted with H$_2$O$_2$, indicating the transformation of trivalent Mn into divalent Mn after reaction with H$_2$O$_2$. The TEM image showed that the nanoparticles became smoother with fewer blackspots on their surface, which is further evidence of Mn$_3$O$_4$ decomposition and abscission from MSNs (Figure 2B).

To estimate the catalytic efficiency of Mn$_3$O$_4$@MSNs@IR780, the time-dependent decomposition of H$_2$O$_2$ was investigated in the presence of Mn$_3$O$_4$@MSNs@IR780. H$_2$O$_2$ was completely decomposed within 3 h (Figure 2C). In addition, single Mn$_3$O$_4$ nanoparticles exhibited similar H$_2$O$_2$ decomposition efficiencies. A portable dissolved oxygen meter was used to identify that the produced bubbles were oxygen. The real-time oxygen concentration increased rapidly after the addition of both Mn$_3$O$_4$ and Mn$_3$O$_4$@MSNs@IR780 into H$_2$O$_2$ solution, while MSNs@IR780 exhibited almost no oxygen-generation ability (Figure 2D). Meanwhile, we have also investigated the dissolution rate of Mn$_3$O$_4$ in various environments in the presence of 1 mM H$_2$O$_2$ and glutathione (GSH) to mimic acidic and oxidative stressed tumor conditions. After 24 h exposure to acidic H$_2$O$_2$ environment, no black dots (Mn$_3$O$_4$) were observed in TEM micrograph (Figure S8A), indicating the complete and successful decomposition of gatekeepers. As shown in Figure S8B, Mn$_3$O$_4$ nanoparticles could disintegrate accelerated into Mn$^{2+}$ ions in acidic environment with at the same H$_2$O$_2$ concentration. The Mn$_3$O$_4$ susceptibility against GSH (most abundant reducing agent exists in solid tumors) is also concerned. The findings in Figure S9 revealed that Mn$_3$O$_4$ nanoparticles could also be disintegrated into Mn$^{2+}$ ions by GSH trigger.

To verify the responsive and triggered release of IR780 in this gatekeeping system, the release profiles of IR780 were recorded by UV-vis-NIR absorption under an in vitro-simulated H$_2$O$_2$-rich tumor microenvironment (Figure 2E). To enhance the release of hydrophobic cargo, we also added a small amount of ethanol to the simulated conditions. In the absence of H$_2$O$_2$, less than 9% of IR780 was released after 12 h, while 35% release of photosensitizer was observed within 6 h in the noncapping condition. Upon exposing the nanocomposite to 1 mM H$_2$O$_2$, a rapid release behavior was observed in the first 6 h, suggesting the oxidant-responsive and controlled release of cargo under tumor-mimicking conditions. We next compared the ROS generation by Mn$_3$O$_4$@MSNs@IR780 and IR780 alone through the fluorescence intensity of oxidized SOSG, as SOSG oxidation led to increased fluorescence in the presence of ROS. The Mn$_3$O$_4$@MSNs@IR780 nanoparticles resulted in the highest accumulation of fluorescence and significantly higher fluorescence than that of IR780 alone under 808 nm laser irradiation. It is remarkable that the PDT activity of Mn$_3$O$_4$@MSNs@IR780 + laser was even weaker than that of the IR780 + laser group in the absence of H$_2$O$_2$, which provided further evidence that these nanoparticles responded only to the tumor microenvironment to release IR780, achieving superior biosafety (Figure 2F). These results demonstrate that these multifunctional biocompatible drug nanocarriers can respond to H$_2$O$_2$-rich environments, intensely increasing the oxygen concentration and successfully releasing drugs to realize mitochondrion-targeted PDT.

**Subcellular localization of Mn$_3$O$_4$@MSNs@IR780**

As a lipophilic cation, IR780 can bind mitochondria specifically due to the higher mitochondrial membrane potential in tumor cells [37,38]. To identify our conjecture that Mn$_3$O$_4$@MSNs@IR780 can inhibit mitochondrial respiration through mitochondrion-targeted PDT, we compared the subcellular localization of Mn$_3$O$_4$@MSNs@IR780 and the designated organelles in vitro. The red signal of Mn$_3$O$_4$@MSNs@IR780 showed extremely similar localization to the green fluorescence of mitochondria. Comparatively, the localization was not similar to that of the green fluorescence of lysosomes, which suggested the mitochondrion targeting of Mn$_3$O$_4$@MSNs@IR780 in cancer cells (Figure 3A). Colocalization analysis of Mn$_3$O$_4$@MSNs@IR780 with mitochondria tracker exhibited a similar trend while lysosome tracker performed different trend (Figure S10). Additionally, the subcellular localization of Mn$_3$O$_4$@MSNs and designated organelles is shown in Figure S11.

**Inhibiting mitochondrial respiration ability in vitro**

The mitochondrion targeting ability of IR780 potentially enlarged the efficacy of PDT because mitochondria are highly susceptible to hyperthermia and ROS. After identifying the mitochondrion-targeting ability of Mn$_3$O$_4$@MSNs@IR780, further experiments were conducted to observe the inhibition
of mitochondrial respiration in vitro. Green fluorescence (ROS) was detected in the IR780 + laser group and the Mn₃O₄@MSNs@IR780 + laser group. The control group exhibited little red fluorescence, showing the hypoxic microenvironment in cancer cells. Meanwhile, obvious red fluorescence representing hypoxia can be observed in the IR780 + laser group, indicating that IR780 will aggravate hypoxia through PDT, whereas Mn₃O₄@MSNs@IR780 produce ROS upon 808 nm laser irradiation without aggravating hypoxia. We also noticed that the red fluorescence disappeared after Mn₃O₄@MSNs@IR780 was added but reappeared after 6 h of coculture, demonstrating that although Mn₃O₄ can generate O₂ in cancer cells, the inhibition of hypoxia is not sustainable. In contrast, 6 h after being treated with Mn₃O₄@MSNs@IR780 + laser, no red fluorescence was observed in cells (Figure 3B). Further flow cytometry using ROS / hypoxia detection probes pointing to the same results (Figure S12).

The data above confirmed our conjecture that due to the mitochondrion targeting ability, Mn₃O₄@MSNs@IR780 can sustainably inhibit mitochondrial respiratory function and thus inhibit the hypoxic microenvironment. Thus, the sustainable inhibition of tumor hypoxia through the PDT approach was first reported and may solve the problems that result from PDT consuming oxygen in the tumor microenvironment, which can lead to poor prognosis, such as recurrence and metastasis.

**Hypoxia detection in cancer cells**

The next purpose was to examine the assumption that Mn₃O₄@MSNs@IR780 could inhibit hypoxia-related signaling pathways. According to western blot results, the cells in the control, laser and IR780 groups exhibited similar expression of HIF-1α with no statistical difference. However, the level of HIF-1α protein in the IR780 + laser group was much higher than in the other groups, demonstrating that PDT therapy alone may result in a more hypoxic

![Figure 3](http://www.thno.org)
microenvironment in cancer cells with a worse prognosis. Comparatively, HIF-1α levels in the Mn_3O_4@MSNs@IR780+ laser group was the lowest among the six groups (Figure 3C). In addition, the HIF-1α protein level in the Mn_3O_4@MSNs@IR780 + laser group was significantly lower than that in the control group (*p = 0.0098), demonstrating that Mn_3O_4@MSNs@IR780 could significantly alleviate tumor hypoxia while consuming oxygen to generate ROS (Figure 3D). Based on the results above, we concluded that Mn_3O_4@MSNs@IR780 could inhibit hypoxia-related signaling pathways, thus enhancing the curative effects of PDT through oxygen generation and the sustained inhibition of mitochondrial respiration.

**ROS generation in cancer cells**

Because of their high cytotoxicity, ROS can kill tumor cells directly [39, 40]. To detect whether Mn_3O_4@MSNs@IR780 could generate ROS in cells upon 808 nm laser irradiation, IR780 and Mn_3O_4@MSNs@IR780 were incubated with MKN-45P cells, and ROS generation was detected by DCFH-DA. The Mn_3O_4@MSNs@IR780 + laser group showed high green fluorescence under an 808 nm laser (1 W·cm⁻², 5 min), suggesting ROS generation (Figure 4A). In contrast, low green fluorescence was observed in cells in the IR780 + laser group, demonstrating that Mn_3O_4@MSNs@IR780 could enhance the PDT effect. The ROS production ability was further quantitatively analyzed using flow cytometry (Figure 4B-C). Cells in the Mn_3O_4@MSNs@IR780 + laser group exhibited the highest fluorescence intensity, which was much higher than that of the IR780 + laser group, while the other groups exhibited negligible fluorescence (IR780 + laser vs Mn_3O_4@MSNs@IR780 + laser, ***p < 0.001). These results confirmed that adequate amounts of ROS could be selectively produced in cancer cells through Mn_3O_4@MSNs@IR780 and NIR irradiation, which meant that Mn_3O_4@MSNs contributed significantly to enhancing the PDT outcome of IR780.

**In vitro therapy against cancer cells**

After identifying the PDT effect and mitochondrion-targeting ability of Mn_3O_4@MSNs@IR780, CAM/PI and the CCK-8 protocol were used to evaluate the cytotoxicity against MKN-45P cells. No obvious red cells were observed in the control group, while a small number of red cells were observed in the laser, IR780 and Mn_3O_4@MSNs@IR780 groups (Figure 4D). Meanwhile, a moderate number of MKN-45P cells were observed in red color after incubation with IR780 and exposure to 808 nm laser irradiation, suggesting less powerful damage against the cancer cells. In the Mn_3O_4@MSNs@IR780 + laser group, almost all MKN-45P cells emitted red fluorescence with no visible green cells. The green cell proportion in these various groups pointed to the same results (Figure 4E). Meanwhile, CCK-8 was used to further detect the in vitro curative effects of Mn_3O_4@MSNs@IR780 upon 808 nm laser irradiation. There were no obvious significant differences in cell viability among the control, laser, IR780 and Mn_3O_4@MSNs@IR780 groups (Figure 4F).

---

**Figure 4. ROS generation and cytotoxicity in MKN-45P cells after different treatments.** (A) CLSM images of ROS generation. The scale bars are 20 μm. (B) Flow cytometry analysis of ROS generation. (C) Mean fluorescence intensities of ROS generation (n = 3). (D) CLSM images of MKN-45P cells using CAM/PI double stain kit as indicators. Green fluorescence indicates live cells and red fluorescence indicates dead cells. The scale bars are 50 μm. (E) Proportion of green cells in total (green and red) cells (n = 3). (F) Relative cell viability using CCK-8 kit (n = 6). Data is shown as mean ± SD. *p < 0.05; **p < 0.01 and ***p < 0.001.
Nevertheless, the cytotoxicity of the Mn₃O₄@MSN@IR780 + laser group was significantly higher than that of the IR780 + laser group when the IR780 concentration was fixed (5 µg mL⁻¹). These results indicate that Mn₃O₄@MSN@IR780 exhibited superior biosafety property in vitro and had a powerful phototherapeutic effect against MKN-45P cells under 808 nm laser irradiation, which could be further used to cure tumors.

**In vivo NIR fluorescence imaging and biodistribution**

After in vitro studies, MKN-45P tumor xenograft models were used for in vivo studies. Our first goal was to determine the appropriate irradiation time point after administration. The tumor accumulation and biodistribution of Mn₃O₄@MSN@IR780 were then monitored through the fluorescent property of IR780 with NIR fluorescence imaging performance ($\lambda_{ex} / \lambda_{em} = 745$ nm / 820 nm). After tail vein injection, real-time NIR images were acquired at different times (Figure 5A). Different colors were used to display different fluorescence intensities, which decreased in the order of red, yellow and blue. The fluorescence signal began to accumulate at the tumor 0.5 h post injection and could be observed in tumor areas 4 h after injection, while the strongest fluorescence signal was detected in tumor tissues 24 h after injection (Figure 5B), indicating the effective accumulation of Mn₃O₄@MSN@IR780 in tumor tissues through the enhanced permeability and retention (EPR) effect. According to the ICP results of manganese content, Mn₃O₄@MSN@IR780 accumulated the most in liver tissues. Additionally, manganese concentration in tumor tissues reach the peak 24 h after injection, showing the same results as in vivo NIR fluorescence imaging (Figure S13).
In vivo monitoring of hypoxic tumor conditions

To further confirm whether Mn₃O₄@MSNs@IR780 can inhibit hypoxia in the tumor area, hypoxic conditions in tumor tissues were detected using PA imaging to measure the dynamics of hypoxia (Hb, 700 nm) and oxygen (HbO₂, 850 nm) in tumor tissues after different treatments (Figure 5C). The highest PA signal of HbO₂ and the lowest of Hb were observed in the Mn₃O₄@MSNs@IR780 + laser group 24 h after injection. Interestingly, the highest PA signal of Hb and the lowest of HbO₂ were observed in the IR780+laser group 24 h after injection. There were no obvious differences among the control, laser, IR780, and Mn₃O₄@MSNs@IR780 groups (Figure 5D-E). These results indicated that Mn₃O₄@MSNs@IR780 can prevent tumor hypoxia by increasing the local oxygen supply.

Afterwards, tumor tissues were harvested for HIF-1α staining to determine whether the hypoxia-related signaling pathways were inhibited (Figure 5F). The IR780 + laser group exhibited a higher HIF-1α level than that in the control, laser, IR780 and Mn₃O₄@MSNs@IR780 groups, while the Mn₃O₄@MSNs@IR780 + laser group showed no detectable elevation in HIF-1α levels compared to the control group (IR780 + laser vs Mn₃O₄@MSNs@IR780 + laser, **p < 0.01), suggesting that the treatment can effectively ameliorate the hypoxic microenvironment while inhibiting the hypoxia signaling pathway of cancer cells.

In vivo antitumor therapy

After indicating that Mn₃O₄@MSNs@IR780 could efficiently kill MKN-45P cells in vitro and ameliorate the hypoxic microenvironment in vivo upon 808 nm laser irradiation, the in vivo antitumor effect was further examined. According to the in vivo NIR imaging and biodistribution results, 24 h was selected as the time point for 808 nm laser irradiation after one i.v. injection (1 W cm⁻², 5 min). The final IR780 concentration was 25 µg·kg⁻¹ per mouse. The control group showed rapid tumor growth with almost no therapeutic effects, while the laser, IR780 and Mn₃O₄@MSNs@IR780 groups showed similar trends to the control group (Figure 6A). For mice in the IR780 + laser group, the tumors grew slowly in the first four days, but unfortunately, they grew rapidly after four days. Thus, we conjectured that the unsustainable inhibition of tumor hypoxia might limit the curative effect and lead to tumor recurrence and poor prognosis. In contrast, almost no increase in tumor volume was observed in the Mn₃O₄@MSNs@IR780 + laser group, indicating a strikingly enhanced therapeutic outcome (IR780 + laser vs Mn₃O₄@MSNs@IR780 + laser, ***p < 0.001). Additionally, the photographs and weights of tumors exhibited almost identical trends to the changes in tumor volume (Figure 6B-C). Combined with the in vitro results, we concluded that Mn₃O₄@MSNs@IR780 could greatly enhance the PDT curative effects to inhibit tumor growth and recurrence mainly because of the enhanced PDT efficacy and inhibition of hypoxia recovery.

Figure 6. Detection of the in vivo anti-tumor effect after different treatments (n = 4). (A) Tumor growth curves. (B-C) Photograph and weight of tumors. The scale bars are 1 cm. (D) H & E staining and TUNEL staining tumor sections. The scale bars are 50 μm. Data is shown as mean ± SD. *p < 0.05; **p < 0.01 and ***p < 0.001.
Figure 7. Biosafety Analysis of different treatments. (A) Ex vivo NIR fluorescence of major organs and tumor tissue 24h after injection of Mn3O4@MSNs@IR780. (B) Fluorescence signal intensity of major organs and tumor tissue (n = 4). (C) H & E staining major organs sections. The scale bars are 50 μm. (D) Hematology assay of white blood cell (WBC), neutrophils (NEU), lymphocytes (LYM), red blood cell (RBC), hemoglobin (HGB) and platelets (PLT) levels (n = 4). (E) Serum biochemical study of alanine aminotransferase (ALT), aspartate aminotransferase (AST), blood urea nitrogen (BUN) and serum creatinine (Scr) levels after different treatments (n = 4). Data is shown as mean ± SD. *p < 0.05; **p < 0.01 and ***p < 0.001.

Biosafety analysis

To evaluate the in vivo biosafety of Mn3O4@MSNs@IR780, NIR fluorescence imaging of main organs and tumor tissues was acquired 24 h after injection (Figure 7A-B). The fluorescent intensity in the tumor (3.4 × 10^7) was significantly higher than the second high fluorescent intensity in the liver (1.08 × 10^7), indicating that Mn3O4@MSNs@IR780 accumulated most in the tumor (***p < 0.001). Next,
major organs, including the heart, liver, spleen, lung and kidney, were collected at the end of different treatments. All groups exhibited negligible inflammation lesions, histological abnormalities and necrosis, which strongly indicated the good biocompatibility of Mn₃O₄@MSNs@IR780 (Figure 7C). In addition, almost no weight fluctuations in the mice were observed during the therapy (Figure 514).

Finally, hematological and biochemical assays were performed to evaluate the potential cytotoxicity of Mn₃O₄@MSNs@IR780 after photodynamic therapy (Figure 7D-E). No significant differences were observed in immune response (WBC, NEU and LYM), cytotoxicity (RBC and HGB), spleen function (PLT), liver function (ALT and AST) and renal function (BUN and Scr) at the end of treatments in all groups compared with the control group. These results verified the high therapeutic biosafety of Mn₃O₄@MSNs@IR780 mainly because of the tumor-targeted drug delivery and treatment, which reduced the side effects on non-tumor organs.

Conclusions

In this study, a Mn₃O₄@MSNs@IR780 nanocomposite was successfully prepared to scavenge the tumor hypoxic microenvironment by self-generating oxygen and the mitochondrion-targeted destruction of respiration in cancer cells, further enhancing PDT efficiency and therapeutic outcome. In vitro studies indicated that Mn₃O₄ nanoparticles could decompose H₂O₂ and sustainably generate oxygen under H₂O₂-rich physiological conditions. During H₂O₂ decomposition, Mn₃O₄ nanoparticles were also designed to leave/dissolve from the MSN surface and thereby enable the release of inner IR780. Afterwards, the released IR780 further specifically targeted the mitochondria and generated ROS to damage their biological function, thus inhibiting respiration in cancer cells. The generation of oxygen and inhibition of cell respiration could alleviate the hypoxic tumor microenvironment, as revealed by ROS/hypoxia imaging in vitro and PA imaging in vivo. The scavenging of tumor hypoxia has also been proven to enhance PDT effects and prevent tumor recurrence, thus leading to a favorable prognosis. In conclusion, this study demonstrated a new approach for sustainably overcoming the hypoxia limitation in traditional PDT by targeted oxygen supplementation and mitochondrial destruction.

Abbreviations

PDT: photodynamic therapy; MSN: mesoporous silica nanoparticle; ROS: reactive oxygen species; DMF: N,N-Dimethylformamide; APTES: 3-aminopropyltriethoxysilane; CTAB: cetyltrimethylammonium bromide; TEOs: tetraethyl orthosilicate; DMSO: dimethyl sulfoxide; EDC-HCl: 1-(3-dimethylamino)propyl)-3-ethylcarbodiimide hydrochloride; H₂O₂: Hydrogen Peroxide; SOSG: Singlet Oxygen Sensor Green; TEM: transmission electron microscope; SEM: scanning electron microscope; PDI: polymer dispersity index; XRD: X-ray diffraction; FTIR: Fourier transform infrared; XPS: X-ray photoelectron spectroscopy; CLSM: confocal laser scanning microscope; HIF-1α: hypoxia-inducible factors-1α; CCK-8: Cell Counting Kit-8; SCID: severe combined immunodeficiency; IACUC: Institutional Animal Care and Use Committee; PA: photacoustic; HBs: Oxygenated hemoglobin; Hb: hemoglobin; H & E: hematoxylin and eosin; WBC: white blood cell; NEU: neutrophils; LYM: lymphocytes; RBC: red blood cell; HGB: hemoglobin; PLT: platelets; ALT: alanine aminotransferase; AST: aspartate aminotransferase; BUN: blood urea nitrogen; Scr: serum creatinine; SD: standard deviation.

Supplementary Material

Supplementary figures and tables. http://www.thno.org/v09p6809s1.pdf

Acknowledgments

This work was supported by grants from the National Natural Science Foundation of China (No. 81372364), the State Commission of Science & Technology of China (2016YFC0104105), the Key Research Plan and Social Development Project of Jiangsu Province, China (BE2016603).

Competing Interests

The authors have declared that no competing interest exists.

References

1. Feng L, Cheng L, Dong Z, Tao D, Barnhart TE, Cai W, et al. Theranostic Liposomes with Hypoxia-Activated Prodrug to Effectively Destruc Tumor Hypoxia during Enhanced Photodynamic Therapy. ACS Nano. 2017; 11: 927-37.
2. Jahanban-Esfahlan R, de la Guardia M, Ahmadi D, Yousefi B. Modulating tumor acidity activating Decorated Metal-Organic Frameworks for Enhanced Photodynamic Therapy. Nanomaterials. 2018; 8: 326.
3. Jahanban-Esfahlan R, de la Guardia M, Ahmadi D, Yousefi B. Modulating tumor acidity activating Decorated Metal-Organic Frameworks for Enhanced Photodynamic Therapy. Nanomaterials. 2018; 8: 326.
4. Gilkes DM, Semenza GL, Wirtz D. Hypoxia and the extracellular matrix: drivers of tumour metastasis. Nat Rev Cancer. 2014; 14: 430-9.
5. Cheng Y, Cheng H, Jiang C, Qiu X, Wang K, Huan W, et al. Perfluorocarbon nanoparticles enhance reactive oxygen levels and tumour growth inhibition in photodynamic therapy. Nat Commun. 2015; 6: 7685.
6. Zhang Y, Wang F, Liu C, Wang Z, Kang L, Huang Y, et al. Nanoyzme Decorated Metal-Organic Frameworks for Enhanced Photodynamic Therapy. ACS Nano. 2018; 12: 651-61.
7. Song X, Feng L, Liang C, Gao M, Song G, Liu Z. Liposomes co-loaded with metformin and chlorin e6 modulate tumor hypoxia during enhanced photodynamic therapy. Nano Research. 2016; 10: 1200-12.
8. Liu J, Liang H, Li M, Luo Z, Zhang J, Guo X, et al. Tumor acidity activating multifunctional nanoplatform for NIR-mediated multiple enhanced
photodynamic and photothermal tumor therapy. Biomater. 2018; 157: 107-24.
9. Zhang M, Cui Z, Song R, Lv B, Tang Z, Meng X, et al. SeiWO4-based nanohybrids with full energy transfer for largely enhanced photodynamic therapy and radiotherapy. Biomater. 2018; 155: 135-44.
10. Yao C, Wang W, Wang P, Zhao M, Li X, Zhang F. Near-Infrared Upconversion Mesoporous Cerium Oxide Hollow Biocatalyst for Concurrent pH-12 O2-Responsive O2-Evolving Synergistic Cancer Therapy. Adv Mater. 2018; 30: 1704383.
11. Liu Y, Liu Y, Bu W, Cheng C, Zuo C, Xiao Q, et al. Hypoxia Induced by Upconversion-Based Photodynamic Therapy: Towards Highly Effective Synergistic Bioreductive Therapy in Tumors. Angew Chem Int Ed Engl. 2015; 54: 8105-9.
12. Kim J, Cho HR, Jeon H, Kim D, Song C, Lee N, et al. Continuous O2-Evolving MnFe2O4 Nanoparticle-Anchored Mesoporous Silica Nanoparticles for Efficient Photodynamic Therapy in Hypoxia Cancer. J Am Chem Soc. 2017; 139: 10992-5.
13. Song M, Liu T, Shi C, Zhang X, Chen X. Bioconjugated Manganese Dioxide Nanoparticles Enhance Chemotherapy Response by Priming Tumor-Associated Macrophages toward M1-like Phenotype and Attenuating Tumor Hypoxia. ACS Nano. 2016; 10: 633-47.
14. Wang W, Cheng Y, Yu P, Wang H, Zhang Y, Xu H, et al. Perfluorocarbon regulates the intratumoral environment to enhance hypoxia-based agent efficacy. Nat Commun. 2019; 10: 1580.
15. Zhang L, Wang D, Yang K, Sheng D, Tan B, Wang Z, et al.Mitochondria-Targeted Artificial ‘Nano-RBCs’ for Amplified Synergistic Cancer Phototherapy by a Single NIR Irradiation. Adv Sci. 2018; 5: 1800049.
16. Day RA, Estabrook DA, Logan JK, Sletten EM. Fluoros photosensitizers enhance photodynamic therapy with perfluorocarbon nanoemulsions. Chem Commun. 2017; 53: 13043-6.
17. Gao M, Liang C, Song X, Chen Q, Jin Q, Wang C, et al. Erythrocyte-Membrane-Enveloped Perfluorocarbon as Nanoscale Artificial Red Blood Cells to Relieve Tumor Hypoxia and Enhance Cancer Radiotherapy. Adv Mater. 2017; 29: 1710429.
18. Gao S, Wang G, Qin Z, Wang X, Zhao G, Ma Q, et al. Oxygen-generating hybrid nanoparticles to enhance fluorescent/photothermal/ultrasound imaging guided tumor photodynamic therapy. Biomaterials. 2017; 112: 324-35.
19. Zhu W, Dong Z, Fu T, Liu J, Chen Q, Li Y, et al. Modulation of Hypoxia in Solid Tumor Microenvironment with MnO2 Nanoparticles to Enhance Photodynamic Therapy. Adv Funct Mater. 2016; 26: 5408-9.
20. Chen Q, Feng L, Liu J, Zhu W, Dong Z, Wu Y, et al. Intelligent Albumin-MnO2 Nanoparticles as pH-12 O2-Responsive Dissociable Nanocarriers to Modulate Tumor Hypoxia for Effective Combination Therapy. Adv Mater. 2016; 28: 7129-36.
21. Liu S, Feng M, Guan W. Mitochondrial DNA sensing by STING signaling participates in inflammation, cancer and beyond. Int J Cancer. 2016; 139: 736-41.
22. Zhou W, Yu H, Zhang L, Wu B, Wang C, Wang Q, et al. Redox-triggered activation of nanocarriers for mitochondria-targeting cancer chemotherapy. Nanoscale. 2017; 9: 17044-53.
23. Zielonka J, Joseph J, Sikora A, Hardy M, Ouari O, Vasquez-Vivar J, et al. Mitochondria-Targeted Triphenylphosphonium-Based Compounds: Syntheses, Mechanisms of Action, and Therapeutic and Diagnostics Applications. Chem Rev. 2017; 117: 10043-120.
24. Jung HS, Lee J-H, Kim K, Koo S, Versvilt P, Sessler JL, et al. A Mitochondria-Targeted Cryptocyanine-Based Photothermogenic Nanoparticle Photocatalyst. J Am Chem Soc. 2013; 135: 9972-8.
25. Zhang C, Liu T, Su Y, Luo S, Zhu Y, Tan X, et al. A near-infrared fluorescent heptamethine indocyanine dye with preferential tumor accumulation for in vivo imaging. Biomaterials. 2010; 31: 6612-7.
26. Han K, Lei Q, Wang S-B, Hu J-J, Qiu W-X, Zhu J-Y, et al. Dual-Stage-Light-Guided Tumor Inhibition by Mitochondria-Targeted Photodynamic Therapy. Adv Funct Mater. 2015; 25: 2961-71.
27. Chakrabartty S, Agrawalla BK, Stumper A, Voci NM, Fischer S, Reichardt C, et al. Mitochondria-Targeted Protein-Ruthenium Photosensitizer for Efficient Photodynamic Applications. J Am Chem Soc. 2017; 139: 2512-9.
28. Murphy MP, Smith RA. Targeting antioxidants to mitochondria by conjugation to lipophilic cations. Annu Rev Pharmacol. 2007; 47: 629-56.
29. Horton KL, Stewart KM, Fonseca SB, Guo Q, Kelley SO. Mitochondria-penetrating peptides. Chem Biol. 2008; 15: 375-82.
30. Ma Z, Jia X, Bai J, Ruan Y, Wang C, Li J, et al. MnO2Gatekeeper: An Intelligent and O2-Evolving Shell for Preventing Premature Release of High Cargo Segments Tumor Payload Core, Overcoming Tumor Hypoxia, and Acidic H2O2-Sensitive MRI. Adv Funct Mater. 2017; 27: 1604258.
31. Lin T, Zhao X, Zhao S, Yu H, Cao W, Chen W, et al. O2-generating MnO2 nanoparticles for enhanced photodynamic therapy of bladder cancer by ameliorating hypoxia. Theranostics. 2018; 8: 990-1004.
32. Ren S, Yang J, Ma L, Li X, Wu W, Liu C, et al. Ternary-Responsive Drug Delivery with Activatable Dual Mode Contrast-Enhanced in vivo Imaging. ACS Appl Mater Inter. 2018; 10: 31947-58.
33. Wang A, Gao M, Wang N, Zhao J, Qi W, Muhammad F, et al. Redox-mediated dissolution of paramagnetic nanolids to achieve a smart theranostic system. Nanoscale. 2014; 6: 5270-8.